Compumedics Limited · ASX:CMP
Compumedics — Bell Potter Healthcare Conference 2023
22 slides from Compumedics's conference presentation, Nov 16, 2023
Slide 1: Corporate presentation
Corporate presentation September 2016 For personal use only Cover sheet to be added – Simone AGM Presentation – October 2023 David Burton – Chairman, CEO dburton@compumedics.com.au David Lawson – Director, CFO dlawson@compumedics.com.au Sleep Diagnostics & Treatment - Neuro Diagnostics - Brain Resea
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Compumedics Limited (CMP). For personal use only While the information in this presentation has been prepared in good faith and with reasonable care, no representation or warranty, express or implied, is made as to the accuracy, adequacy or reliabili
Slide 3: Who is Compumedics?
Who is Compumedics? For personal use only Compumedics is a leading global medical technology company focused on: Compumedics is Australia-based, with wholly owned offices in the USA, •Monitoring sleep and diagnosing sleep disorders Compumedics is a technology leader Germany, France, Austria and Kore
Slide 4: What does Compumedics do?
• We develop and design innovative medical technology, What does devices, Software as a Service (SaaS) and accessories Compumedics do? for: For personal use only • Monitoring sleep and diagnosing sleep disorders • Monitoring neurological disorders • Highly sophisticated brain research • Ultrasonic m
Slide 5: What does Compumedics sell?
What does Compumedics sell? For personal use only Sleep diagnostics and monitoring Neurology monitoring
Slide 6: What has Compumedics done so far?
What has Compumedics done so far? For personal use only We have sold more than 30,000 medical systems around the world since Compumedics was founded in 1987 and generated about $800m in revenues in that time, 85% of which is export. We sold sleep diagnostic technology to NASA as part of the space sh
Slide 7: What has Compumedics done so far?
What has Compumedics done so far? For personal use only We set up our direct office in the USA in 2000 and have operated in the USA for more than 20 years currently with a team of about 40 We have traded in Asia for more than 25 years, with long term distributor relationships in China, Japan and oth
Slide 8: Revenue Composition at $42.4m
Revenue Composition at $42.4m • 30 June 2023 – Geographic and product diversification serves us well For personal use only By geographic region By product/market Customer Consumables Care 8% Europe, USA, Brain - 10% 26% 28% Blood Flow Monitoring Sleep - 15% Clinical Diagnostics 32% Brain - Research
Slide 9: FY2023 – Highlights
FY2023 – Highlights For personal use only • Core Business Revenues grew 12% to a record $42.4m for FY23, compared to $37.8m in FY22. Despite a full-year FY23 EBITDA loss of ($2.0), driven by MEG write-offs, EBITDA returned to profit in H2 FY23 at $2.8m. Substantial investment in commercialisation ac
Slide 10: Core Business: early FY24 pointers
Core Business: early FY24 pointers For personal use only ➢ Q1 FY24 sales orders taken are 23% higher than same time last year, driven by strong growth in Australia because of the initial commercialisation of Somfit ➢ The MEG system is currently being installed at TJNU in China and as a result Q1 FY2
Slide 11: Core Business: early FY24 highlights
Core Business: early FY24 highlights For personal use only ➢ Australia-based Okti sales expand as key hospitals move to our latest generation neurological monitoring platform ➢ Okti is a best-in-class ambulatory, home or clinical EEG monitoring device, scalable from 32 channels up to 256 channels fo
Slide 12: Core Business: FY24 drivers
Core Business: FY24 drivers For personal use only ➢ Compumedics will launch Falcon HST at the Australian Sleep Meeting in Adelaide next month. Falcon is a new generation of home or professional user experience for the home sleep testing (HST) market ➢ Falcon HST will fully integrate with Compumedics
Slide 13: The Somfit and Somfit Pro Systems
The Somfit and Somfit Pro Systems For personal use only Somfit – 4 components, Somfit Pro – 5 components Consumable revenue Capital cost or built into SaaS fees Recurring SaaS fee to access
Slide 14: Existing Home sleep diagnostic process is cumbersome
Existing Home sleep diagnostic process is cumbersome For personal use only From this….. To this…..
Slide 15: Superior value proposition
Superior value proposition For personal use only Somfit provides a more comfortable, convenient, and cost-effective way to assess and monitor sleep health • Highly scalable: quality health SaaS business model • Clinical grade at home device: Light and comfortable for the patient while enabling colle
Slide 16: Somfit – FY24 drivers
Somfit – FY24 drivers For personal use only Several near-term opportunities have been identified for Somfit. There are three key benefits to targeting these shorter-term opportunities: • Profitable short-term revenues are a real-life validation of the system and marketing strategy • Profitable short
Slide 17: Australian market development – FY24
Australian market development – FY24 For personal use only H2 FY2024. Roll out to existing non-HST providers Q2 FY2024. signed-up and sign- Sign-up potential up a further Pharmacy HST pharmacy-based service provider. providers. Start Somfit GP program. Q1 FY2024. Roll out to pharmacy-based HST Pharm
Slide 18: USA market development – FY24
USA market development – FY24 For personal use only In the USA there are about 3,000 sleep centers and 15 major Independent Diagnostic Testing Facilities (IDTF’s). These will be our H4 FY2024. Roll out to initial target addressable initial HST providers whilst further HST market service providers ar
Slide 19: MEG – FY24 drivers
MEG – FY24 drivers For personal use only • The MEG system for TJNU in China has moved through major technical milestones and shipped to TJNU during Q1 FY24 • The TJNU system is currently being installed on site and is expected to be completed late November, early December 2024 • The Company will boo
Slide 20: Directors & Executive Team
Directors & Executive Team Key Management For personal use only David Burton, Ph.D. Executive Chairman, CEO Founder, Tenure 36 yrs Rod North Mr. David Lawson Non-Executive Director Chief Financial Officer CMP Tenure 1 year & Company Secretary CMP Tenure 24 yrs Mr. Warwick Freeman Kerry Hubick, Ph.D.
Slide 21: Investor Summary
Investor Summary Core business profitable with on-going growth opportunities in key global markets For personal use only International sales force Compumedics remains expansion, neurology and committed to continuing to sleep market opportunity and deliver superior returns to earnings improvement sha
Slide 22: For personal use only
For personal use only compumedics.com.au 22